<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36737245</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle><i>UNC13A</i> in amyotrophic lateral sclerosis: from genetic association to therapeutic target.</ArticleTitle><Pagination><StartPage>649</StartPage><EndPage>656</EndPage><MedlinePgn>649-656</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2022-330504</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options and an incompletely understood pathophysiology. Although genomewide association studies (GWAS) have advanced our understanding of the disease, the precise manner in which risk polymorphisms contribute to disease pathogenesis remains unclear. Of relevance, GWAS have shown that a polymorphism (rs12608932) in the <i>UNC13A</i> gene is associated with risk for both ALS and frontotemporal dementia (FTD). Homozygosity for the C-allele at rs12608932 modifies the ALS phenotype, as these patients are more likely to have bulbar-onset disease, cognitive impairment and FTD at baseline as well as shorter survival. UNC13A is expressed in neuronal tissue and is involved in maintaining synaptic active zones, by enabling the priming and docking of synaptic vesicles. In the absence of functional TDP-43, risk variants in <i>UNC13A</i> lead to the inclusion of a cryptic exon in <i>UNC13A</i> messenger RNA, subsequently leading to nonsense mediated decay, with loss of functional protein. Depletion of <i>UNC13A</i> leads to impaired neurotransmission. Recent discoveries have identified <i>UNC13A</i> as a potential target for therapy development in ALS, with a confirmatory trial with lithium carbonate in <i>UNC13A</i> cases now underway and future approaches with antisense oligonucleotides currently under consideration. Considering <i>UNC13A</i> is a potent phenotypic modifier, it may also impact clinical trial outcomes. This present review describes the path from the initial discovery of <i>UNC13A</i> as a risk gene in ALS to the current therapeutic options being explored and how knowledge of its distinct phenotype needs to be taken into account in future trials.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willemse</LastName><ForeName>Sean W</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-0198-5740</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harley</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><Identifier Source="ORCID">0000-0002-7132-5967</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demaegd</LastName><ForeName>Koen C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelina</LastName><ForeName>Pavol</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasterkamp</LastName><ForeName>R Jeroen</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Department of Neurology, KU Leuven Hospital, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, VIB KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rheenen</LastName><ForeName>Wouter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-5572-9657</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9054-026X</Identifier><AffiliationInfo><Affiliation>Bushell Chair of Neurology, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands M.A.vanEs@umcutrecht.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S006508/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/W005190/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">neurobiology</Keyword><Keyword MajorTopicYN="N">neurogenetics</Keyword><Keyword MajorTopicYN="N">neuromuscular</Keyword></KeywordList><CoiStatement>Competing interests: PVD has served in advisory boards for Biogen, CSL Behring, Alexion Pharmaceuticals, Ferrer, QurAlis, Cytokinetics, Argenx, UCB, Muna Therapeutics, Alector, Augustine Therapeutics, VectorY (paid to institution). LHvdB declares fees to his institution from Biogen, Wave, Amylyx, Ferrer, and Cytokinetics for being on a scientific advisory board; fees to his institution from Amylyx for a lecture; an unrestricted educational grant from Takeda; and is the Chair of ENCALS and TRICALS. MAvE has consulted for Biogen and has received travel grants from Shire (formerly Baxalta) and serves as medical monitor for Ferrer in the ADORE trial (NCT05178810).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36737245</ArticleId><ArticleId IdType="pmc">PMC10359588</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2022-330504</ArticleId><ArticleId IdType="pii">jnnp-2022-330504</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet 2017;390:2084&#x2013;98. 10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;55. 10.1016/S0140-6736(10)61156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;12. 10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, et al. . Riluzole for amyotrophic lateral sclerosis (ALS) /motor neuron disease (MND). Cochrane Database Syst Rev 2007;CD001447. 10.1002/14651858.CD001447.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub2</ArticleId><ArticleId IdType="pubmed">12076411</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, et al. . Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics 2017;14:762&#x2013;72. 10.1007/s13311-016-0508-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. . Long-Term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve 2021;63:31&#x2013;9. 10.1002/mus.27091</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, et al. . Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 2016;15:1182&#x2013;94. 10.1016/S1474-4422(16)30199-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Halliday GM, Kril JJ, et al. . The frontotemporal dementia-motor neuron disease continuum. Lancet 2016;388:919&#x2013;31. 10.1016/S0140-6736(16)00737-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Harvey C, Zhang S, et al. . Advances in the genetic classification of amyotrophic lateral sclerosis. Curr Opin Neurol 2021;34:756&#x2013;64. 10.1097/WCO.0000000000000986</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000986</ArticleId><ArticleId IdType="pmc">PMC7612116</ArticleId><ArticleId IdType="pubmed">34343141</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Higashihara M, Sobue G, et al. . Als is a multistep process in South Korean, Japanese, and Australian patients. Neurology 2020;94:e1657&#x2013;63. 10.1212/WNL.0000000000009015</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009015</ArticleId><ArticleId IdType="pmc">PMC7251515</ArticleId><ArticleId IdType="pubmed">32071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617&#x2013;28. 10.1038/nrneurol.2013.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, McLaughlin RL, et al. . Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol 2019;76:1367&#x2013;74. 10.1001/jamaneurol.2019.2044</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.2044</ArticleId><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, et al. . Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet 2021;53:1636&#x2013;48. 10.1038/s41588-021-00973-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, et al. . TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2020;92:86&#x2013;95. 10.1136/jnnp-2020-322983</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Ke YD, Ittner LM, et al. . Als/Ftld: experimental models and reality. Acta Neuropathol 2017;133:177&#x2013;96. 10.1007/s00401-016-1666-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1666-6</ArticleId><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, et al. . Tdp-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 2022;603:124&#x2013;30. 10.1038/s41586-022-04424-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A-L, Wilkins OG, Keuss MJ, et al. . Tdp-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 2022;603:131&#x2013;7. 10.1038/s41586-022-04436-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17&#x2013;23. 10.1038/nn.3584</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Smukowski SN, Maioli H, Latimer CS, et al. . Progress in amyotrophic lateral sclerosis gene discovery. Neurol Genet 2022;8:e669. 10.1212/NXG.0000000000000669</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000669</ArticleId><ArticleId IdType="pmc">PMC9128037</ArticleId><ArticleId IdType="pubmed">35620141</ArticleId></ArticleIdList></Reference><Reference><Citation>Visscher PM, Brown MA, McCarthy MI, et al. . Five years of GWAS discovery. Am J Hum Genet 2012;90:7&#x2013;24. 10.1016/j.ajhg.2011.11.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.11.029</ArticleId><ArticleId IdType="pmc">PMC3257326</ArticleId><ArticleId IdType="pubmed">22243964</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich KA, Roggenbuck J, Kolb SJ. Searching far and genome-wide: the relevance of association studies in amyotrophic lateral sclerosis. Front Neurosci 2020;14:603023. 10.3389/fnins.2020.603023</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.603023</ArticleId><ArticleId IdType="pmc">PMC7873947</ArticleId><ArticleId IdType="pubmed">33584177</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Mok K, Newhouse S, et al. . Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol 2010;9:986&#x2013;94. 10.1016/S1474-4422(10)70197-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70197-6</ArticleId><ArticleId IdType="pmc">PMC3257853</ArticleId><ArticleId IdType="pubmed">20801717</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CGJ, et al. . Genome-Wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 2009;41:1083&#x2013;7. 10.1038/ng.442</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.442</ArticleId><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaksovirta H, Peuralinna T, Schymick JC, et al. . Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol 2010;9:978&#x2013;85. 10.1016/S1474-4422(10)70184-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70184-8</ArticleId><ArticleId IdType="pmc">PMC2965392</ArticleId><ArticleId IdType="pubmed">20801718</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245&#x2013;56. 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008;322:881&#x2013;8. 10.1126/science.1156409</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1156409</ArticleId><ArticleId IdType="pmc">PMC2694957</ArticleId><ArticleId IdType="pubmed">18988837</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam V, Patel N, Turcotte M, et al. . Benefits and limitations of genome-wide association studies. Nat Rev Genet 2019;20:467&#x2013;84. 10.1038/s41576-019-0127-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-019-0127-1</ArticleId><ArticleId IdType="pubmed">31068683</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PWJ, van Rheenen W, et al. . UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging 2012;33:630. 10.1016/j.neurobiolaging.2011.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.029</ArticleId><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmeti KB, Ajroud-Driss S, Al-Chalabi A, et al. . Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. Neurobiol Aging 2013;34:357. 10.1016/j.neurobiolaging.2012.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.017</ArticleId><ArticleId IdType="pmc">PMC3839234</ArticleId><ArticleId IdType="pubmed">22959728</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Taboada JM, Lopez-Lopez A, Salvado M, et al. . UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J Neurol 2015;262:2285&#x2013;92. 10.1007/s00415-015-7843-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7843-z</ArticleId><ArticleId IdType="pubmed">26162714</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, et al. . Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 2016;48:1043&#x2013;8. 10.1038/ng.3622</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, et al. . Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 2018;97:1268&#x2013;83. 10.1016/j.neuron.2018.02.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020;581:434&#x2013;43. 10.1038/s41586-020-2308-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida A, Takahashi A, Deng M, et al. . Replication analysis of snps on 9p21.2 and 19p13.3 with amyotrophic lateral sclerosis in east asians. Neurobiol Aging 2011;32:757. 10.1016/j.neurobiolaging.2010.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.12.011</ArticleId><ArticleId IdType="pubmed">21295378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Huang R, Chen Y, et al. . Association analysis of four candidate genetic variants with sporadic amyotrophic lateral sclerosis in a Chinese population. Neurol Sci 2014;35:1089&#x2013;95. 10.1007/s10072-014-1656-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-014-1656-1</ArticleId><ArticleId IdType="pubmed">24493373</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Jiang H, Wang F, et al. . UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis. Neurol Sci 2019;40:2293&#x2013;302. 10.1007/s10072-019-03951-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03951-y</ArticleId><ArticleId IdType="pubmed">31201598</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HHG, Westeneng H-J, van der Burgh HK, et al. . The distinct traits of the UNC13A polymorphism in amyotrophic lateral sclerosis. Ann Neurol 2020;88:796&#x2013;806. 10.1002/ana.25841</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25841</ArticleId><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="pubmed">32627229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Restagno G, et al. . UNC13A influences survival in italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol Aging 2013;34:357. 10.1016/j.neurobiolaging.2012.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.016</ArticleId><ArticleId IdType="pmc">PMC3483408</ArticleId><ArticleId IdType="pubmed">22921269</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, Baer GM, Elman L, et al. . UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2019;73:190&#x2013;9. 10.1016/j.neurobiolaging.2018.09.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.031</ArticleId><ArticleId IdType="pmc">PMC6251755</ArticleId><ArticleId IdType="pubmed">30368160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Hernandez DG, Nalls MA, et al. . Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 2014;13:686&#x2013;99. 10.1016/S1474-4422(14)70065-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70065-1</ArticleId><ArticleId IdType="pmc">PMC4112126</ArticleId><ArticleId IdType="pubmed">24943344</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Ren Y, Perkerson RB, et al. . Genome-Wide analyses as part of the International FTLD-TDP whole-genome sequencing Consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol 2019;137:879&#x2013;99. 10.1007/s00401-019-01962-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01962-9</ArticleId><ArticleId IdType="pmc">PMC6533145</ArticleId><ArticleId IdType="pubmed">30739198</ArticleId></ArticleIdList></Reference><Reference><Citation>Govaarts R, Beeldman E, Kampelmacher MJ, et al. . The frontotemporal syndrome of ALS is associated with poor survival. J Neurol 2016;263:2476&#x2013;83. 10.1007/s00415-016-8290-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8290-1</ArticleId><ArticleId IdType="pmc">PMC5110703</ArticleId><ArticleId IdType="pubmed">27671483</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, Van Deerlin VM, van Swieten JC, et al. . C9Orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. Ann Neurol 2014;76:120&#x2013;33. 10.1002/ana.24198</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24198</ArticleId><ArticleId IdType="pmc">PMC4137231</ArticleId><ArticleId IdType="pubmed">24931836</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Wen N, Fan CC, et al. . Selective genetic overlap between amyotrophic lateral sclerosis and diseases of the frontotemporal dementia spectrum. JAMA Neurol 2018;75:860&#x2013;75. 10.1001/jamaneurol.2018.0372</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0372</ArticleId><ArticleId IdType="pmc">PMC6043387</ArticleId><ArticleId IdType="pubmed">29630712</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics 1974;77:71&#x2013;94. 10.1093/genetics/77.1.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/genetics/77.1.71</ArticleId><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Brose N, Hofmann K, Hata Y, et al. . Mammalian homologues of Caenorhabditis elegans unc-13 gene define novel family of C2-domain proteins. J Biol Chem 1995;270:25273&#x2013;80. 10.1074/jbc.270.42.25273</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.42.25273</ArticleId><ArticleId IdType="pubmed">7559667</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch H, Hofmann K, Brose N. Definition of Munc13-homology-domains and characterization of a novel ubiquitously expressed Munc13 isoform. Biochem J 2000;349:247&#x2013;53. 10.1042/bj3490247</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3490247</ArticleId><ArticleId IdType="pmc">PMC1221144</ArticleId><ArticleId IdType="pubmed">10861235</ArticleId></ArticleIdList></Reference><Reference><Citation>Quade B, Camacho M, Zhao X, et al. . Membrane bridging by Munc13-1 is crucial for neurotransmitter release. eLife 2019;8:1&#x2013;30. 10.7554/eLife.42806</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.42806</ArticleId><ArticleId IdType="pmc">PMC6407922</ArticleId><ArticleId IdType="pubmed">30816091</ArticleId></ArticleIdList></Reference><Reference><Citation>Betz A, Thakur P, Junge HJ, et al. . Functional interaction of the active zone proteins Munc13-1 and Rim1 in synaptic vesicle priming. Neuron 2001;30:183&#x2013;96. 10.1016/S0896-6273(01)00272-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00272-0</ArticleId><ArticleId IdType="pubmed">11343654</ArticleId></ArticleIdList></Reference><Reference><Citation>Varoqueaux F, Sigler A, Rhee J-S, et al. . Total arrest of spontaneous and evoked synaptic transmission but normal synaptogenesis in the absence of Munc13-mediated vesicle priming. Proc Natl Acad Sci U S A 2002;99:9037&#x2013;42. 10.1073/pnas.122623799</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.122623799</ArticleId><ArticleId IdType="pmc">PMC124419</ArticleId><ArticleId IdType="pubmed">12070347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarebidaki F, Camacho M, Brockmann MM, et al. . Disentangling the roles of rim and Munc13 in synaptic vesicle localization and neurotransmission. J Neurosci 2020;40:9372&#x2013;85. 10.1523/JNEUROSCI.1922-20.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1922-20.2020</ArticleId><ArticleId IdType="pmc">PMC7724145</ArticleId><ArticleId IdType="pubmed">33139401</ArticleId></ArticleIdList></Reference><Reference><Citation>Siksou L, Varoqueaux F, Pascual O, et al. . A common molecular basis for membrane docking and functional priming of synaptic vesicles. Eur J Neurosci 2009;30:49&#x2013;56. 10.1111/j.1460-9568.2009.06811.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2009.06811.x</ArticleId><ArticleId IdType="pubmed">19558619</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y, Choi UB, Leitz J, et al. . Molecular mechanisms of synaptic vesicle priming by Munc13 and Munc18. Neuron 2017;95:591&#x2013;607. 10.1016/j.neuron.2017.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.004</ArticleId><ArticleId IdType="pmc">PMC5747255</ArticleId><ArticleId IdType="pubmed">28772123</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof TC. Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 2013;80:675&#x2013;90. 10.1016/j.neuron.2013.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.022</ArticleId><ArticleId IdType="pmc">PMC3866025</ArticleId><ArticleId IdType="pubmed">24183019</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdziarek M, Bolembach AA, Stepien KP, et al. . Re-Examining how Munc13-1 facilitates opening of syntaxin-1. Protein Sci 2020;29:1440&#x2013;58. 10.1002/pro.3844</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3844</ArticleId><ArticleId IdType="pmc">PMC7255523</ArticleId><ArticleId IdType="pubmed">32086964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Li W, Xu Y, et al. . Munc13 mediates the transition from the closed syntaxin&#x2013;Munc18 complex to the SNARE complex. Nat Struct Mol Biol 2011;18:542&#x2013;9. 10.1038/nsmb.2047</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2047</ArticleId><ArticleId IdType="pmc">PMC3087822</ArticleId><ArticleId IdType="pubmed">21499244</ArticleId></ArticleIdList></Reference><Reference><Citation>Grushin K, Kalyana Sundaram RV, Sindelar CV, et al. . Munc13 structural transitions and oligomers that may choreograph successive stages in vesicle priming for neurotransmitter release. Proc Natl Acad Sci U S A 2022;119:e2121259119. 10.1073/pnas.2121259119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2121259119</ArticleId><ArticleId IdType="pmc">PMC8851502</ArticleId><ArticleId IdType="pubmed">35135883</ArticleId></ArticleIdList></Reference><Reference><Citation>Varoqueaux F, Sons MS, Plomp JJ, et al. . Aberrant morphology and residual transmitter release at the Munc13-deficient mouse neuromuscular synapse. Mol Cell Biol 2005;25:5973&#x2013;84. 10.1128/MCB.25.14.5973-5984.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.14.5973-5984.2005</ArticleId><ArticleId IdType="pmc">PMC1168806</ArticleId><ArticleId IdType="pubmed">15988013</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu J, Betz A, Brose N, et al. . Munc13-1 C1 domain activation lowers the energy barrier for synaptic vesicle fusion. J Neurosci 2007;27:1200&#x2013;10. 10.1523/JNEUROSCI.4908-06.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4908-06.2007</ArticleId><ArticleId IdType="pmc">PMC6673179</ArticleId><ArticleId IdType="pubmed">17267576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Li Y, Gong J, et al. . Munc18 and Munc13 serve as a functional template to orchestrate neuronal SNARE complex assembly. Nat Commun 2019;10:69. 10.1038/s41467-018-08028-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-08028-6</ArticleId><ArticleId IdType="pmc">PMC6325239</ArticleId><ArticleId IdType="pubmed">30622273</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy-Alla S, B&#xf6;hme MA, Reynolds E, et al. . Stable positioning of unc13 restricts synaptic vesicle fusion to defined release sites to promote synchronous neurotransmission. Neuron 2017;95:1350&#x2013;64. 10.1016/j.neuron.2017.08.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.08.016</ArticleId><ArticleId IdType="pubmed">28867551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton BJ, Husch A, Schaffran B, et al. . An active vesicle priming machinery suppresses axon regeneration upon adult CNS injury. Neuron 2022;110:51&#x2013;69. 10.1016/j.neuron.2021.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.10.007</ArticleId><ArticleId IdType="pmc">PMC8730507</ArticleId><ArticleId IdType="pubmed">34706221</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee JS, Betz A, Pyott S, et al. . Beta phorbol ester- and diacylglycerol-induced augmentation of transmitter release is mediated by Munc13s and not by PKCs. Cell 2002;108:121&#x2013;33. 10.1016/s0092-8674(01)00635-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(01)00635-3</ArticleId><ArticleId IdType="pubmed">11792326</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Calakos N. Munc13-1 is required for presynaptic long-term potentiation. J Neurosci 2011;31:12053&#x2013;7. 10.1523/JNEUROSCI.2276-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2276-11.2011</ArticleId><ArticleId IdType="pmc">PMC3201725</ArticleId><ArticleId IdType="pubmed">21849565</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho M, Basu J, Trimbuch T, et al. . Heterodimerization of Munc13 C2A domain with RIM regulates synaptic vesicle docking and priming. Nat Commun 2017;8:15293. 10.1038/ncomms15293</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15293</ArticleId><ArticleId IdType="pmc">PMC5436228</ArticleId><ArticleId IdType="pubmed">28489077</ArticleId></ArticleIdList></Reference><Reference><Citation>He E, Wierda K, van Westen R, et al. . Munc13-1 and Munc18-1 together prevent NSF-dependent de-priming of synaptic vesicles. Nat Commun 2017;8:15915. 10.1038/ncomms15915</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15915</ArticleId><ArticleId IdType="pmc">PMC5482055</ArticleId><ArticleId IdType="pubmed">28635948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittman JS. Unc13: a multifunctional synaptic marvel. Curr Opin Neurobiol 2019;57:17&#x2013;25. 10.1016/j.conb.2018.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2018.12.011</ArticleId><ArticleId IdType="pmc">PMC6629506</ArticleId><ArticleId IdType="pubmed">30690332</ArticleId></ArticleIdList></Reference><Reference><Citation>Junge HJ, Rhee J-S, Jahn O, et al. . Calmodulin and Munc13 form a Ca2+ sensor/effector complex that controls short-term synaptic plasticity. Cell 2004;118:389&#x2013;401. 10.1016/j.cell.2004.06.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2004.06.029</ArticleId><ArticleId IdType="pubmed">15294163</ArticleId></ArticleIdList></Reference><Reference><Citation>Calloway N, Gouzer G, Xue M, et al. . The active-zone protein Munc13 controls the use-dependence of presynaptic voltage-gated calcium channels. Elife 2015;4:1&#x2013;15. 10.7554/eLife.07728</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.07728</ArticleId><ArticleId IdType="pmc">PMC4525472</ArticleId><ArticleId IdType="pubmed">26196145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipstein N, Chang S, Lin K-H, et al. . Munc13-1 is a Ca2+-phospholipid-dependent vesicle priming hub that shapes synaptic short-term plasticity and enables sustained neurotransmission. Neuron 2021;109:3980&#x2013;4000. 10.1016/j.neuron.2021.09.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.09.054</ArticleId><ArticleId IdType="pmc">PMC8691950</ArticleId><ArticleId IdType="pubmed">34706220</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel AG, Selcen D, Shen X-M, et al. . Loss of Munc13-1 function causes microcephaly, cortical hyperexcitability, and fatal myasthenia. Neurol Genet 2016;2:e105. 10.1212/NXG.0000000000000105</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000105</ArticleId><ArticleId IdType="pmc">PMC5017540</ArticleId><ArticleId IdType="pubmed">27648472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipstein N, Verhoeven-Duif NM, Michelassi FE, et al. . Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder. J Clin Invest 2017;127:1005&#x2013;18. 10.1172/JCI90259</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90259</ArticleId><ArticleId IdType="pmc">PMC5330740</ArticleId><ArticleId IdType="pubmed">28192369</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziortzouda P, Van Den Bosch L, Hirth F. Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci 2021;22:197&#x2013;208. 10.1038/s41583-021-00431-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00431-1</ArticleId><ArticleId IdType="pubmed">33654312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, et al. . Tdp-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 2015;349:650&#x2013;5. 10.1126/science.aab0983</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, et al. . Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci 2019;12:25. 10.3389/fnmol.2019.00025</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi K, Ideno H, Sato T, et al. . Pathogenic mutation of TDP-43 impairs RNA processing in a cell type-specific manner: implications for the pathogenesis of ALS/FTLD. ENeuro 2022;9:ENEURO.0061-22.2022. 10.1523/ENEURO.0061-22.2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0061-22.2022</ArticleId><ArticleId IdType="pmc">PMC9186108</ArticleId><ArticleId IdType="pubmed">35641224</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin A-C, Burr K, Borooah S, et al. . Human iPSC-derived motoneurons harbouring TARDBP or C9orf72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun 2015;6:5999. 10.1038/ncomms6999</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6999</ArticleId><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer MS, Reale LA, Lewis KE, et al. . Mislocalisation of TDP-43 to the cytoplasm causes cortical hyperexcitability and reduced excitatory neurotransmission in the motor cortex. J Neurochem 2021;157:1300&#x2013;15. 10.1111/jnc.15214</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15214</ArticleId><ArticleId IdType="pubmed">33064315</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper DC, Adachi Y, Sutcliffe B, et al. . Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum Mol Genet 2013;22:1539&#x2013;57. 10.1093/hmg/ddt005</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt005</ArticleId><ArticleId IdType="pmc">PMC3605831</ArticleId><ArticleId IdType="pubmed">23307927</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Sideris DI, Carroll E, et al. . Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol 2018;135:213&#x2013;26. 10.1007/s00401-017-1797-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1797-4</ArticleId><ArticleId IdType="pmc">PMC5773656</ArticleId><ArticleId IdType="pubmed">29273900</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Bospoort R, Farina M, Schmitz SK, et al. . Munc13 controls the location and efficiency of dense-core vesicle release in neurons. J Cell Biol 2012;199:883&#x2013;91. 10.1083/jcb.201208024</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201208024</ArticleId><ArticleId IdType="pmc">PMC3518216</ArticleId><ArticleId IdType="pubmed">23229896</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardar G, Chang S, Arancillo M, et al. . Distinct functions of syntaxin-1 in neuronal maintenance, synaptic vesicle docking, and fusion in mouse neurons. J Neurosci 2016;36:7911&#x2013;24. 10.1523/JNEUROSCI.1314-16.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1314-16.2016</ArticleId><ArticleId IdType="pmc">PMC6601879</ArticleId><ArticleId IdType="pubmed">27466336</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao C-L, Liu Y-T, Zhou ZH, et al. . Accumulation of dense core vesicles in hippocampal synapses following chronic inactivity. Front Neuroanat 2018;12:1&#x2013;11. 10.3389/fnana.2018.00048</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2018.00048</ArticleId><ArticleId IdType="pmc">PMC6004418</ArticleId><ArticleId IdType="pubmed">29942253</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia AM, Gallo A, Manzari C, et al. . Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci Rep 2017;7:10046. 10.1038/s41598-017-10488-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10488-7</ArticleId><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsu M, Hama Y, Utsumi J, et al. . Microrna expression profiles of neuron-derived extracellular vesicles in plasma from patients with amyotrophic lateral sclerosis. Neurosci Lett 2019;708:134176. 10.1016/j.neulet.2019.03.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.03.048</ArticleId><ArticleId IdType="pubmed">31173847</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F, Longone P, Cafaro L, et al. . Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008;105:2052&#x2013;7. 10.1073/pnas.0708022105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0708022105</ArticleId><ArticleId IdType="pmc">PMC2538879</ArticleId><ArticleId IdType="pubmed">18250315</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison KE, Dhariwal S, Hornabrook R, et al. . Lithium in patients with amyotrophic lateral sclerosis (licals): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013;12:339&#x2013;45. 10.1016/S1474-4422(13)70037-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70037-1</ArticleId><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, Veldink JH, Huisman MHB, et al. . Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 2012;83:557&#x2013;64. 10.1136/jnnp-2011-302021</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-302021</ArticleId><ArticleId IdType="pubmed">22378918</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G. The final chapter of the ALS lithium SAGA. Lancet Neurol 2013;12:324&#x2013;5. 10.1016/S1474-4422(13)70040-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70040-1</ArticleId><ArticleId IdType="pubmed">23453346</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Jones AR, Sproviero W, et al. . Meta-Analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 2017;89:1915&#x2013;22. 10.1212/WNL.0000000000004606</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemse SW, Roes KCB, Van Damme P, et al. . Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial. Trials 2022;23:978. 10.1186/s13063-022-06906-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-022-06906-5</ArticleId><ArticleId IdType="pmc">PMC9721045</ArticleId><ArticleId IdType="pubmed">36471413</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza OV, De-Paula VJR, Diniz BSO. Neuroprotective effects of lithium: implications for the treatment of Alzheimer&#x2019;s disease and related neurodegenerative disorders. ACS Chem Neurosci 2014;5:443&#x2013;50. 10.1021/cn5000309</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn5000309</ArticleId><ArticleId IdType="pmc">PMC4063497</ArticleId><ArticleId IdType="pubmed">24766396</ArticleId></ArticleIdList></Reference><Reference><Citation>Limanaqi F, Biagioni F, Ryskalin L, et al. . Molecular mechanisms linking ALS/FTD and psychiatric disorders, the potential effects of lithium. Front Cell Neurosci 2019;13:450. 10.3389/fncel.2019.00450</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00450</ArticleId><ArticleId IdType="pmc">PMC6797817</ArticleId><ArticleId IdType="pubmed">31680867</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquali L, Longone P, Isidoro C, et al. . Autophagy, lithium, and amyotrophic lateral sclerosis. Muscle Nerve 2009;40:173&#x2013;94. 10.1002/mus.21423</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21423</ArticleId><ArticleId IdType="pubmed">19609902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D. Promise of nucleic acid therapeutics for amyotrophic lateral sclerosis. Ann Neurol 2022;91:13&#x2013;20. 10.1002/ana.26259</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26259</ArticleId><ArticleId IdType="pubmed">34704267</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone B, La Cognata V, Sprovieri T, et al. . Alternative splicing of ALS genes: misregulation and potential therapies. Cell Mol Neurobiol 2020;40:1&#x2013;14. 10.1007/s10571-019-00717-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-019-00717-0</ArticleId><ArticleId IdType="pubmed">31385134</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, et al. . Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723&#x2013;32. 10.1056/NEJMoa1702752</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez ER, Borschel WF, Traynor BJ. New antisense oligonucleotide therapies reach first base in ALS. Nat Med 2022;28:25&#x2013;7. 10.1038/s41591-021-01629-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01629-7</ArticleId><ArticleId IdType="pubmed">35075291</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco FA, Czikora A, Kedei N, et al. . Munc13 is a molecular target of bryostatin 1. Biochemistry 2019;58:3016&#x2013;30. 10.1021/acs.biochem.9b00427</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.9b00427</ArticleId><ArticleId IdType="pmc">PMC6620733</ArticleId><ArticleId IdType="pubmed">31243993</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Nikolakopoulos S, et al. . Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure? Pharmacogenomics J 2020;20:220&#x2013;6. 10.1038/s41397-019-0111-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41397-019-0111-3</ArticleId><ArticleId IdType="pubmed">31624333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. . Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol 2021;17:104&#x2013;18. 10.1038/s41582-020-00434-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>